Pharvaris says phase 3 RAPIDe-3 trial shows oral deucrictibant speeds symptom relief in HAE attacks

• Pharvaris reported Phase 3 RAPIDe-3 results for oral deucrictibant to treat hereditary angioedema attacks, now published in The Lancet.
• Results were previously presented via the study readout, not flagged for a future conference presentation.
• Deucrictibant shortened time to symptom relief and full resolution versus placebo, with most attacks controlled using one oral dose.
• Safety was described as well tolerated, with no new safety signals reported in the pivotal trial.
• Regulators are reviewing the U.S. NDA and EU MAA for on-demand use, with an FDA PDUFA target date of April 23, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610081835PRIMZONEFULLFEED9842272) on October 08, 2026, and is solely responsible for the information contained therein.